Comparison of nonabsorbable markers Poly R-478 and [14C]PEG-4,000 for use in developmental absorption studies

Effects of casoxin 4 on morphine inhibition of small animal intestinal contractility and gut transit in the mouse

Background and aims:

Chronic opioid analgesia has the debilitating side-effect of constipation in human patients. The major aims of this study were to: 1) characterize the opioid-specific antagonism of morphine-induced inhibition of electrically driven contraction of the small intestine of mice, rats, and guinea pigs; and 2) test if the oral delivery of small milk-derived opioid antagonist peptides could block morphine-induced inhibition of intestinal transit in mice.

Methods:

Mouse, rat, and guinea pig intact ileal sections were electrically stimulated to contract and inhibited with morphine in vitro. Morphine inhibition was then blocked by opioid subtype antagonists in the mouse and guinea pig. Using a polymeric dye, Poly R-478, the opioid antagonists casoxin 4 and lactoferroxin A were tested orally for blocking activity of morphine inhibition of gut transit in vivo by single or double gavage techniques.

Results:

The guinea pig tissue was more sensitive to morphine inhibition compared with the mouse or the rat (IC₅₀ [half maximal inhibitory concentration] values as nmol/L ± SEM were 34 ± 3, 230 ± 13, and 310 ± 14 respectively) (P < 0.01). The inhibitory influence of opioid agonists (IC₅₀) in electrically driven ileal mouse preparations were DADLE ([D-Ala², D-Leu⁵]-enkephalin) ≥ met-enkephalin ≥ dynorphin A ≥ DAMGO ([D-Ala², N-Me-Phe⁴, Glyol⁵]-enkephalin) > morphine > morphiceptin as nmol/L 13.9, 17.3, 19.5, 23.3, 230, and 403 respectively. The mouse demonstrated predominantly κ- and δ-opioid receptor activity with a smaller μ-opioid receptor component. Both mouse and guinea pig tissue were sensitive to casoxin 4 antagonism of morphine inhibition of contraction. In contrast to naloxone, relatively high oral doses of the μ-opioid receptor antagonists, casoxin 4 and lactoferroxin A, applied before and after morphine injection were unable to antagonize morphine inhibition of gut transit.

Conclusions:

Casoxin 4 reverses morphine-induced inhibition of contraction in mice and guinea pigs in vitro but fails to influence morphine inhibition of mouse small intestinal transit by the oral route.

Site specific delivery of microencapsulated fish oil to the gastrointestinal tract of the rat

The aim of this study was to design food grade matrices to deliver microencapsulated fish oil to the large bowel of the rat where the potential exists to retard inflammation and cancer development. Digestion in simulated gastric fluid and intestinal fluid demonstrated that only 4-6% of oil was released from the following dried emulsion formulations: 50% fish oil encapsulated in heated casein-glucose-dried glucose syrup (1:1:1) (Cas-Glu-DGS-50); 25% fish oil in casein-modified resistant starch (Hylon VII) (1:1) (Cas-Hylon-25); or 25% fish oil in Cas-Glu-Hylon (1:1:1) (Cas-Glu-Hylon-25). A short-term gavage study (0-12 h) with fish oil and Cas-Glu-DGS-50 demonstrated the appearance of fish oil long chain (LC) n-3 polyunsaturated fatty acids (PUFA) into the plasma indicating specific small intestinal absorption with little LC n-3 PUFA reaching the large bowel. In a 2-week-long term, daily gavage study, the bioavailability of fish oil and fish oil in Cas-Glu-DGS-50 or Cas-Hylon-25 demonstrated that fish oil and Cas-Glu-DGS-50 LC n-3 PUFA were incorporated into the tissue of the small intestine and colon, whereas Cas-Hylon-25 was resistant to degradation in the small intestine. The use of modified Hylon VII for targeted colonic delivery was confirmed in the final short-term gavage study (0-14 h) using Cas-Glu-Hylon-25 with [(14)C]-trilinolenin as a marker incorporated into the microcapsules, where up to 60% of the labeled oil reached the large bowel. Depending on the microencapsulating matrix employed, fish oil can be delivered selectively to the small intestine or to a high degree to the large bowel.

Dietary arachidonic acid and docosahexaenoic acid elevate femur calcium and reduce zinc content in piglets

Specific dietary polyunsaturated fatty acids (PUFAs) and long chain PUFAs (LCPUFAs) elevate femur calcium content and enhance calcium balance. Mother's milk is associated with enhanced calcium balance and contains LCPUFAs; arachidonic acid (AA), and docosahexanoic acid (DHA). However, the effect of AA and DHA on calcium metabolism and other bone minerals during infancy is unknown. Thus, piglets received one of four formulas (15 d): control or with AA:DHA (0.5:0.1 g, 1.0:0.2 g, or 2.0:0.4 g/100 g of fat). Calcium absorption, femur mineral composition, and urinary mineral excretion. Main effects identified using two-way analysis of variance (ANOVA) and post hoc analysis conducted using Duncan's multiple range test. Significant effects of diet were observed in femur calcium and zinc content, but not calcium absorption, urinary mineral excretion, femur ash weight, femur phosphorus, or femur magnesium content. The piglets receiving AA:DHA as 1.0:0.2 g/100 g of fat had 1.9% higher mg calcium/g of ash, but 8.6% lower mug zinc/g of ash compared with control. Thus, AA:DHA in a ratio of 5:1 does not affect mineral accretion, but AA plus DHA, in amounts similar to the upper limit of human milk, might be detrimental to bone mineralization over time due to lower zinc.

Oxyntomodulin and glicentin are potent inhibitors of the fed motility pattern in small intestine

Glicentin (GLIC) and oxyntomodulin (OXM or GLIC 33-69) are gut hormones which regulate digestion. They are known to reduce digestive secretions and to delay gastric emptying. Their biological activities on intestinal motility are still unknown. The effect of a systemic GLIC or OXM increase was investigated in rats on the food intake, the postprandial myoelectrical activity of small intestine and the orocaecal transit. An OXM or GLIC i.v. infusion was applied during the 5 min preceding food onset and during the first 15 min of food intake. This determined a three- to fourfold increase of the preprandial OXM-GLIC level. The OXM or GLIC plasma increase did not modify food intake. OXM infusion slowed down gastric emptying when the stomach contained 3/4 of the ingested food (before T 3 h). The quantity of food delivered in jejunum was subsequently smaller (P < 0.05). In the small intestine, the duration of postprandial myoelectrical activity (50-60 min g(-1) of ingested food) was reduced by 70% (P < 0.001) on duodenum or jejunum and by 54% (P < 0.01) on ileum in OXM-treated rats. An interdigestive motility profile was settled and an acceleration of both gastric emptying and transit rate was thereafter evidenced (after T 3 h). GLIC also reduced the duration of the postprandial myoelectrical activity on duodenum and jejunum (65 and 63% respectively, P < 0.05), but was not as efficient as OXM on ileum. In pathological states such as acute adult gastroenteritis, OXM and GLIC exhibit a two- to fivefold increase in their plasma concentrations. The present findings suggest that OXM and GLIC could, in that disease, contribute to exclude pathogens, due to their joined action on gut motility.

Proximal intestinal absorption of calcium is elevated in proportion to growth rate but not bone mass is small for gestational age piglets

During the first year of life, body calcium content increases faster in relation to body size than any other time during growth. Studies have shown postnatal growth and bone mineralization differences between appropriate for gestational age and small for gestational age infants. The objective of this study was to compare duodenal calcium transport using intestinal ligated loop technique in 21-day-old small for gestational age (birth weight of <1.2 kg) and appropriate for gestational age piglets (birth weight of > or =1.4 kg). Piglets were fed liquid formula between day 5 and 21 of life and monitored daily for weight gain. At day 21 calcium absorption was measured followed by measurement of bone mass using dual energy x-ray absorptiometry. Small for gestational age piglets had greater calcium absorption and growth rate than appropriate for gestational age piglets. Birth weight was negatively related to weight gain and calcium absorption. Weight gain was positively related to calcium absorption. Appropriate for gestational age piglets had significantly higher whole body bone mineral content than small for gestational age piglets even after correction for body size. Whole body bone mineral content was positively correlated with birth weight and negatively correlated with calcium absorption. These observations suggest that small for gestational age piglets are capable of absorbing elevated amounts of calcium in the proximal intestine in support of compensatory growth. However, at 21 days of age small for gestational age piglets are similar in size but have lower bone mass compared to appropriate for gestational age piglets.

Digestion and absorption of ferulic acid sugar esters in rat gastrointestinal tract

We estimated the absorption site and absorptivity of ferulic acid (FA) and its sugar esters, namely 5-O-feruloyl-l-arabinofuranose (FAA) and feruloyl-arabinoxylan (FAXn), in rats on the basis of their recovery in intestinal content and feces by comparing the values with those of a nonabsorbable marker, poly R-478. The results indicated that free FA was absorbed almost completely before reaching cecum. About 40% of dietary FAA was absorbed in rat foregut and 57% disappeared in the cecum. In contrast, about 67% of the FA moiety in FAXn was released and then disappeared predominantly in the hindgut. These results suggested that the existing form of FA in diets affects its absorptivity, its absorption site, and its ensuing fate in the gastrointestinal tract. Those ingested FAs esterified with saccharides; especially, polysaccharides have to transit the hindgut where FA might be released and then absorbed and/or degraded by microflora in lumen. Such microbial degradation may be an important factor affecting the bioavailability of dietary FA.

Dietary supplementation of arachidonic acid is associated with higher whole body weight and bone mineral density in growing pigs

Essential fatty acids are fundamental to normal growth and development, but North American formulas do not contain arachidonic (AA) and docosahexaenoic acid (DHA). The main objective of the present study was to determine whether addition of AA and DHA to formula elevates growth and bone mineralization in piglets. A secondary objective was to establish whether liver fatty acid composition is related to that of bone. Twelve 10-d-old male piglets were randomized to receive either a standard formula with an n-6:n-3 fatty acid ratio of 4.9:1.0 or the same formula made with an equal amount of fat but containing AA (0.5% wt/wt total fat) and DHA (0.1% wt/wt total fat) for 14 d. Piglets in the supplemented group had significantly (p < 0.05) higher weight and greater bone mineral density of the whole body, lumbar spine, and femur. No differences were observed in whole body length, calcium absorption, or biochemical markers of bone metabolism. Feeding AA resulted in lower linoleic acid (p < 0.05) and higher (p < 0.05) AA in liver total lipid (% wt/wt) and bone FFA (% wt/wt) but no change to DHA. Liver AA (% wt/wt total lipid) was positively related (p < 0.05) to growth, free AA (% wt/wt) in bone, bone mineral content, bone mineral density, and urinary prostaglandin E2 but negatively related (p < 0.05) to free linoleic acid in bone. Inverse relationships were observed when liver linoleic acid was substituted for liver AA as the independent variable. These data indicate that feeding AA is associated with elevated weight and higher whole body and regional bone mineral density.

Milk-borne epidermal growth factor modulates intestinal transforming growth factor-alpha levels in neonatal rats

Epidermal growth factor (EGF) is present in milk from various mammalian species, but its physiologic function in neonatal development remains unclear. Transforming growth factor-alpha (TGF-alpha) is a peptide structurally related to EGF, and its presence is detected in the developing small intestine of rats. The purpose of the present study was to examine the effect of milk-borne EGF on endogenous production of EGF and TGF-alpha in the small intestine of suckling rats. Neonatal rats were fed via gastrostomy either growth factor-free rat milk substitute (RMS) or RMS supplemented with EGF (100 ng/mL of RMS) from 8 to 12 d of age. Artificially reared rats were then compared with their dam-fed littermates. Animals fed the EGF-deficient diet RMS had markedly increased EGF and TGF-alpha mRNA levels in duodenum and ileum compared with dam-fed controls and significantly elevated total intestinal content of TGF-alpha peptide. Intestinal EGF content and EGF serum levels were significantly decreased in the RMS group compared with controls. The addition of EGF to the RMS diet normalized TGF-alpha mRNA levels in the duodenum and ileum, EGF mRNA levels in the ileum, and total intestinal TGF-alpha content and EGF serum levels to the levels measured in dam-fed littermates. Motility studies showed that enteral administration of EGF did not affect stomach emptying and intestinal transit. These studies indicate that exogenous milk-borne EGF modulates endogenous production of TGF-alpha in developing small intestine. It is likely that neither TGF-alpha nor EGF are solely responsible for small intestinal overgrowth of artificially reared neonatal rats.

Epidermal growth factor delays gastric emptying and small intestinal transit in suckling rats

Suckling (12-d-old) rats that were fasted for 15 h received epidermal growth factor (EGF) s.c. (0.5 and 1.0 microgram per rat, i.e. approximately 2 and 4 micrograms/100 g of body weight), together with motility markers 51Cr-EDTA or Poly R-478, and were killed 45 min later. Counts were measured separately in the stomach and the small intestine, which was divided into 12 segments. Administration of EGF delayed gastric emptying. In controls, the stomach contained 26.1 +/- 1.6% (mean +/- SEM); in EGF-treated rats the stomach contained 75.9 +/- 10.2% and 75.7 +/- 2.5% of the total 51Cr-EDTA counts given. EGF had the maximum effect (1.0 microgram) when given simultaneously with 51Cr-EDTA. Significant, but lower, effects of EGF were seen with the administration of EGF preceded by 10 min or followed by 10 and 20 min with the administration of 51Cr-EDTA (65.8 +/- 5.8%, 60.0 +/- 6.4%, and 54.1 +/- 4.2%, respectively). Small intestinal transit was also delayed. Administration of anti-EGF antiserum did not affect gastric emptying, but accelerated small intestinal transit as determined 30 min after administration of 51Cr-EDTA. These studies are the first to demonstrate the effect of EGF on gastrointestinal motility in vivo in suckling mammals.

Developmental regulation of epidermal growth factor receptor kinase in rat intestine

BACKGROUND/AIMS

Intraluminal epidermal growth factor (EGF) may regulate intestinal growth and function. The ontogeny, localization, and phosphorylation of the EGF receptor in rat small intestine were studied.

METHODS

EGF-receptor phosphorylation was assayed by antiphosphotyrosine Western blot after EGF administration in vivo and EGF incubation to everted sacs in vitro. EGF-receptor abundance and localization were assayed by Western blot and immunofluorescence using anti-EGF-receptor antibodies.

RESULTS

In vivo, orogastric EGF enhanced EGF-receptor phosphorylation in newborn rat jejunum and liver. However, intraluminal EGF had no effect on EGF-receptor phosphorylation in adult intestine or liver. In vitro, mucosal EGF stimulated a fourfold increase in EGF-receptor phosphorylation in suckling jejunum but not in weanling or adult jejunum. In Western blot, EGF-receptor abundance was similar in 22-day-old fetal, 8-day-old suckling, and adult jejunum. In both crypt and villus, EGF-receptor was localized to the basolateral membrane but not to the apical membrane in fetal, suckling, and adult jejunum.

CONCLUSIONS

Mucosal EGF stimulates EGF-receptor phosphorylation in immature but not in mature intestine. These differences are not explained by EGF-receptor abundance or localization and suggest that the greater mucosal permeability of the immature gut may allow EGF to bind to the EGF-receptor in the basolateral membrane to mediate its effects in suckling rat intestine.

Passive jejunal bile salt absorption alters the enterohepatic circulation in immature rats

BACKGROUND

Developmental changes in passive bile salt absorption may alter the enterohepatic circulation.

METHODS

14-, 21-, and 40-day-old anesthetized male Sprague-Dawley rats were studied. Jejunum and ileum were isolated, cannulated, and injected or perfused with a taurocholate, [3H]taurocholate, and nonabsorbable marker solution. Bile was collected.

RESULTS

Using bolus injection, jejunal taurocholate absorption rates and total taurocholate absorption were nonsaturable, linearly related to taurocholate dose, and decreased from 14 days (1.62 nmol.cm-1.min-1) to 21 days (1.05 nmol.cm-1.min-1) and 40 days (0.54 nmol.cm-1.min-1). While total taurocholate absorption decreased (14 days, 52.4%; 21 days, 43.7%; 40 days, 30.5%), hepatic taurocholate clearance increased (14 days, 18.2%; 21 days, 23.7%; 40 days, 37.3%). Hepatic taurocholate clearance was saturated only at 14 days. Using jejunal perfusion, total taurocholate absorption (14 days, 62.0%; 21 days, 43.1%; 40 days, 45.3%) and taurocholate absorption rate decreased with age (14 days, 941.13 nmol.cm-2.min-1 per micromole of taurocholate; 21 days, 411.28 nmol.cm-2.min-1 per micromole of taurocholate; 40 days, 334.50 nmol.cm-2.min-1 per micromole of taurocholate).

CONCLUSIONS

Passive jejunal bile salt absorption and decreased hepatic bile salt clearance could account for the low intraluminal and high serum bile salt levels observed in immature animals and in human neonates.